Swedish biotech Camurus (Nasdaq Stockholm: CAMX) has secured EU marketing authorization for its once-monthly acromegaly ...

Systemic sclerosis is an autoimmune connective tissue disease that causes debilitating fibrosis of the skin and internal ...

Denmark-based Vesper Bio, a biotech developing an oral therapy for frontotemporal dementia, has announced the appointment of ...

Shares in US biotech INmune Bio slumped by around 60% following news that its Phase II Alzheimer’s study failed to hit its ...

Clinical-stage oncology company Revolution Medicines and fellow USA-based Summit Therapeutics have entered into a clinical ...

As pressure builds around drug pricing and access, US trade group PhRMA is pushing back against criticism of pharmaceutical ...

The US Food and Drug Administration (FDA) has approved Japanese pharma major Takeda’s Gammagard Liquid ERC [immune globulin ...

Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious ...

Acquisitions in Alzheimer’s drug development have soared, with deal value jumping from $2 billion in 2022 to nearly $18 ...

Japanese drugmaker Shionogi (TYO: 4507) has filed a supplemental application in Japan to broaden the use of its oral ...

US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders ...

US mRNA specialist Moderna today announced positive results from a Phase III efficacy study (P304) evaluating the relative ...